TANOX REPORTS 48-WEEK RESULTS FROM TNX-355 TRIAL

A A

Tanox has reported 48-week results from its Phase II clinical trial of HIV drug candidate, TNX-355. Following previously reported 24-week data, the new results show that HIV-infected patients who received either study dose of TNX-355, in combination with an optimized background regimen (OBR), maintained a considerably greater reduction in viral load than did patients given placebo in combination with OBR.

At 48 weeks, treatment with a 10 mg/kg dose of TNX-355 resulted in a mean viral-load reduction of 0.96 log10, compared with a 0.14 log10 reduction in the placebo group, representing a 0.82 log10 greater reduction in viral load. Patients who received a 15 mg/kg dose of TNX-355 had a mean viral-load reduction of 0.71 log10, compared with a 0.14 log10 reduction in the placebo group, representing a 0.57 log10 greater reduction in viral load.